- Home
- Who We Are
About Us
Qu Biologics has attracted a team of life sciences professionals who are leaders in their respective fields.
- What We Do
What We Do
Qu Biologics’ SSIs restore innate immune function and reverse the chronic inflammation underlying many conditions such as cancer and immune-related disease.
- Clinical Trials
Clinical Trials
Investigational treatment QBECO SSI is an immunotherapy aimed at restoring normal immune function to reverse the chronic inflammation underlying Crohn’s disease.
- Partner With Us
Partner With Us
To gain a better understanding of the root causes of disease and the potential benefits of novel immunotherapies, Qu Biologics has a number of university research collaborations.
- Qu In The News
- Careers
Careers
Join a team of innovators who have a passion to make a difference. In a short time, our ambitious team has achieved a number of major milestones and we have many big goals ahead.
- Contact Us
Ulcerative Colitis
See the results from our Phase 2 open-label clinical trial in ulcerative colitis here.
Do you have ulcerative colitis?
Reversing Chronic Inflammation Underlying Ulcerative Colitis
There is growing evidence that defect or suppression of the innate immune system may underlie a variety of immune-related diseases, including ulcerative colitis. Qu Biologics is developing Site Specific Immunomodulators (SSIs), designed to restore the body’s normal immune response. In the case of ulcerative colitis, QBECO SSI, derived from components of inactivated E. coli, is designed to restore innate immune function in the colon and reverse the chronic inflammation and dysbiosis associated with the disease. Read more about how SSIs restore normal immune function.
Qu Biologics’ clinical trial in ulcerative colitis
Qu Biologics has completed a Phase 2 open-label clinical trial in ulcerative colitis. A summary of the results from this Health Canada-approved trial can be found here.
If you are interested in keeping up to date on the status of Qu Biologics’ clinical research into ulcerative colitis, you may sign up to receive updates.
If at any time you have any questions, you may email ulcerativecolitis@quibd.com.
Join our IBD Community Advisory Panel
If you are someone living with inflammatory bowel disease or are a caregiver, we’d like to hear from you! You could make a difference in how our clinical trials are designed. Learn more about joining our IBD Community Advisory Panel.
For more information on our clinical program in ulcerative colitis visit www.quibd.com.